These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 8033141)

  • 1. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
    Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
    Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
    Lieschke GJ; Maher D; O'Connor M; Green M; Sheridan W; Rallings M; Bonnem E; Burgess AW; McGrath K; Fox RM
    Cancer Res; 1990 Feb; 50(3):606-14. PubMed ID: 2404573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer.
    Saleh MN; Khazaeli MB; Wheeler RH; Bucy RP; Liu T; Everson MP; Munn DH; Schlom J; LoBuglio AF
    Cancer Res; 1995 Oct; 55(19):4339-46. PubMed ID: 7671245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: a phase ib clinical study.
    Herrmann F; Schulz G; Lindemann A; Meyenburg W; Oster W; Krumwieh D; Mertelsmann R
    Behring Inst Mitt; 1988 Aug; (83):107-18. PubMed ID: 2467645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.
    Jakubowski AA; Bajorin DF; Templeton MA; Chapman PB; Cody BV; Thaler H; Tao Y; Filippa DA; Williams L; Sherman ML; Garnick MB; Houghton AN
    Clin Cancer Res; 1996 Feb; 2(2):295-302. PubMed ID: 9816172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.
    Cole DJ; Sanda MG; Yang JC; Schwartzentruber DJ; Weber J; Ettinghausen SE; Pockaj BA; Kim HI; Levin RD; Pogrebniak HW
    J Natl Cancer Inst; 1994 Jan; 86(1):39-45. PubMed ID: 8271281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of therapy with recombinant granulocyte-macrophage colony-stimulating factor administered by IV bolus or continuous infusion.
    Rifkin RM; Hersh EM; Salmon SE
    Behring Inst Mitt; 1988 Aug; (83):125-33. PubMed ID: 3071327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
    Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J
    Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors].
    Berthaud P; Eugène-Jolchine I; Spielmann M; Le Chevalier T; Tursz T
    Bull Cancer; 1993 May; 80(5):418-30. PubMed ID: 8173195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
    Janik JE; Miller LL; Kopp WC; Taub DD; Dawson H; Stevens D; Kostboth P; Curti BD; Conlon KC; Dunn BK; Donegan SE; Ullrich R; Alvord WG; Gause BL; Longo DL
    Clin Immunol; 1999 Dec; 93(3):209-21. PubMed ID: 10600331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-related complex.
    Kaplan LD; Abrams DI; Sherwin SA; Kahn J; Volberding PA
    Biotechnol Ther; 1989-1990; 1(3):229-36. PubMed ID: 2562651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
    Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial.
    Schmidinger M; Steger G; Wenzel C; Locker GJ; Budinsky AC; Brodowicz T; Kramer G; Marberger M; Zielinski CC;
    J Immunother; 2001; 24(3):257-62. PubMed ID: 11394504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
    Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
    Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.